- United States
- /
- Pharma
- /
- NasdaqGM:OMER
Retail investors who hold 53% of Omeros Corporation (NASDAQ:OMER) gained 10%, institutions profited as well
Key Insights
- Significant control over Omeros by retail investors implies that the general public has more power to influence management and governance-related decisions
- 41% of the business is held by the top 25 shareholders
- Institutions own 43% of Omeros
A look at the shareholders of Omeros Corporation (NASDAQ:OMER) can tell us which group is most powerful. With 53% stake, retail investors possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
While retail investors were the group that benefitted the most from last week’s US$29m market cap gain, institutions too had a 43% share in those profits.
In the chart below, we zoom in on the different ownership groups of Omeros.
Check out our latest analysis for Omeros
What Does The Institutional Ownership Tell Us About Omeros?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
We can see that Omeros does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Omeros' earnings history below. Of course, the future is what really matters.
We note that hedge funds don't have a meaningful investment in Omeros. BlackRock, Inc. is currently the largest shareholder, with 6.0% of shares outstanding. Ingalls & Snyder, LLC is the second largest shareholder owning 5.9% of common stock, and The Vanguard Group, Inc. holds about 4.8% of the company stock. Furthermore, CEO Gregory Demopulos is the owner of 3.0% of the company's shares.
On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
Insider Ownership Of Omeros
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
Our most recent data indicates that insiders own some shares in Omeros Corporation. In their own names, insiders own US$12m worth of stock in the US$312m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.
General Public Ownership
The general public -- including retail investors -- own 53% of Omeros. With this amount of ownership, retail investors can collectively play a role in decisions that affect shareholder returns, such as dividend policies and the appointment of directors. They can also exercise the power to vote on acquisitions or mergers that may not improve profitability.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Omeros better, we need to consider many other factors. For instance, we've identified 3 warning signs for Omeros (2 don't sit too well with us) that you should be aware of.
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:OMER
Omeros
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
High growth potential with slight risk.
Similar Companies
Market Insights
Community Narratives

